Zedira Transglutaminase Services

Based on our profound expertise in transglutaminase, celiac disease and related fields, Zedira supports your R&D-work on a fee-for-service base.


Services on Transglutaminase in Research and Development

Service categories include, but are not limited to:
  • Production of transglutaminases from animal species (if not already listed in our product catalogue)
  • Modification of transglutaminases (biotin, fluorescent labels, …)
  • Development of transglutaminase assays for customer specific applications
  • Determination of human and animal transglutaminase inhibition in drug development
  • Organic synthesis of small transglutaminase related molecules (e.g. substrates, inhibitors)

Services on determination of Microbial Transglutaminase (MTG)

Microbial Transglutaminase is widely used in food applications. At Zedira we provide services for determination and detection of MTG in your sample.

Service categories include, but are not limited to:
  • Determination of microbial transglutaminase activity in food preparations (FAQ - Determination of MTG activity.pdf)
  • Determination of microbial transglutaminase protein in food preparations
  • Determination of gluten/gliadin content in food and food preparations

Whatever you need - a product or a service around transglutaminase or related fields, please do not hesitate to contact us.

Phone: +49 6151 3251-00
E-mail: contact@zedira.com

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events

  • Gordon Research Conference on: Transglutaminases in Human Disease Processes

    16.06.2018 - 17.06.2018
    Les Diablerets, Switzerland